Philadelphia and Malvern, Pennsylvania USA. April 3^rd, 2023.  Myto Health LLC, a biotech company with R and D facilities in Malvern PA, a suburb of Philadelphia, is launched. Improving mitochondrial health is the focus of the company and its impact on aging and chronic diseases. Mitochondria are the energy factories of the cells and play a fundamental role in health. Dysfunction or damage to mitochondria is the major cause of neurodegeneration, such as Alzheimer’s and Parkinson’s disease (AD and PD). Mitochondrial dysfunction is also the root cause of many chronic diseases and aging. Myto Health has established a small molecule screening platform, and discovered molecules from natural product libraries that target damaged mitochondria, promote repair, and regenerate new mitochondria. These natural products are generally safe, and potential to have a major impact on human health without approval from FDA (nutraceuticals).  Myto Health has shown that damage to mitochondria can be reversed by small molecules discovered at the company. Myto Health science has demonstrated that small molecules induce new mitochondrial biogenesis overcome disease, restore neuronal and muscle cell function to elevate many chronic diseases such as memory, cognition, muscle function, and metabolic diseases. Similarly, the company has rationally designed small molecule that target mitochondria to improve Parkinson’s disease functions in cellular and animal models. Core expertise to study neurodegeneration such as AD and PD will help the company in development of nutraceuticals, pharmaceuticals, and blood-based biomarkers for aging. Dr. Tauseef Butt, leading principal of Myto Health said “we believe that small molecules that promote mitochondrial health will reverse aging process as well as have a big impact in overcoming chronic disease”.   For more details, please consult Myto Health Website www.mytohealth.net 

Contact:

Ms. Sarah Thomas

Business Development Manager

[email protected]

Phone: 610-644-6974 EXT 301